Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

Migliori G. B., Lange C., Girardi E., Centis R., Besozzi G., Kliiman K., Codecasa L. R., Spanevello A., Cirillo D. M., the SMIRA/TBNET Study Group

Source: Eur Respir J 2008; 31: 904-905

Journal Issue: April

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Migliori G. B., Lange C., Girardi E., Centis R., Besozzi G., Kliiman K., Codecasa L. R., Spanevello A., Cirillo D. M., the SMIRA/TBNET Study Group. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. Eur Respir J 2008; 31: 904-905

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012
Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021
Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004
Aminoglycoside ototoxicity monitoring in multidrug resistant tuberculosis: How much is enough? Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Source: Eur Respir Rev 2009; 18: 195-197 Year: 2009
Treating multiple-drug resistant tuberculosis Source: International Congress 2018 – PG13 Challenges in the treatment of tuberculosis Year: 2018
Multidrug resistant tuberculosis: clinical aspects and management Source: Eur Respir J 2001; 18: Suppl. 33, 235s Year: 2001
Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017